While research is being done in all possible ways to thwart the Coronavirus that has caused the deaths of millions of people around the world. There are currently no drugs that work directly on Covid. As a precautionary measure, only vitamin tablets, antibody-enhancing drugs, vaccines such as Remdesivir injection, Covaxin, and Covishield are only available. They also know that there is a shortage. On the other hand, there is a concern in India as deaths are increasing day by day. In this context, there is widespread interest in the emergence of a rapidly fighting drug against the virus.
All the way from Georgia
In collaboration with the Georgia State University, the National Institutes of Health (NIH) in the United States, and the University of Plymouth in the United Kingdom, in collaboration with scientists, the drug Molnupiravir (MK-4482), which is in its final stages of development, is now of global interest. This antiviral drug, which is proposed to inhibit covid, can be taken orally. While developing it for a variety of viruses (influenza), experiments have begun on how to use it to curb Covid. Experiments on rats were completed and positive results were obtained. The next step will be experimenting with other animals. So far, with the exception of immunosuppressive tablets and antiviral tablets, it remains a tablet specifically designed to fight deadly viruses such as Covid. Doctors at the University of Georgia say the tablet is effective in fighting the virus in the respiratory system as well as diluting the blood. Molnupiravir was given to mice 12 hours before and 12 hours after corona infection, and it was found that the drug protected them from the virus. Not only that .. even if this single drug is given in combination with other antiviral drugs .. it will be made in such a way that there are no side effects. The experiments will be performed on humans until the next stage. The experiments will be performed in different countries of the world in three stages. The respective countries will then examine and approve the effect, results and side effects of this drug. According to the information coming out so far … Scientists are hopeful that they will find another strong weapon to fight Covid in these experiments which will have the same positive results on humans as the first phase experiments.
FBL application in India
Fermenta Biotech Limited (FBL), a company based in Maharashtra, has developed a biocatalyst manufacturing method using the same formula domestically. Applied for a patent. Prashant Nagare, CEO of the company, commented to the media that the technology is environmentally friendly as well as producing medicine at low cost.
Prevent the spread
Nature Microbiology Magazine reports that the drug controls the virus and reduces the spread of the virus. The magazine revealed that these experiments also took place. Within 24 hours the drug was found to be effective.
Remdesivir to give orally
Under the current circumstances, there is a huge demand in the market for the injection of Remdesivir used for Covid control. The same thing is happening with the black market. Governments have imposed restrictions on the price of these injections, but there are allegations that they are charging higher prices in many places. In the case of Telugu states, Remdesivir is being manufactured by Hetero in Hyderabad at about 34,000 doses per day and Mylan at 37,000 doses per day. This means that only a maximum of 71,000 injections is produced per day. However, as these injections have to be sent to other states as well, the injections are available to the Telugu states only up to a maximum of 8,000 per day. Cadila Healthcare, Sinjin International, Reddy’s Laboratories, Cipla and Jubilant Generics are currently licensed to manufacture this injection across the country. Altogether, it is planned to manufacture 38.8 lakh injections. Of these, 10 lakh injections (vials) were given emergency approval (fast tracks) permits. At the same time, there is a huge demand and research is being done on alternative routes.
Jubilant Pharma recently announced the development of oral Remdesivir. This oral medicine is designed to last for five days. The company has already revealed that it has been successful in security-related tests. The Drug Controller General of India (DCGI) has sought permission for further studies. If these experiments are successful, the drug can be given orally (inhaler model). Jubilant chairman Shyam Bhartia and co-chairman Hari Bhartia told the media that there would be a shortage of injections at the same time.
